Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Regenxbio
(NASDAQ:RGNX)
Intraday
$16.00
0.10
[0.63%]
After-Hours
$16.00
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$16.00
0.10
[0.63%]
At close: Apr 24
$16.00
0
[0.00%]
After Hours: 4:16PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Regenxbio Stock (NASDAQ:RGNX)
Regenxbio Stock (NASDAQ: RGNX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, April 12, 2024
Where Regenxbio Stands With Analysts
Benzinga Insights
-
Apr 12, 2024, 12:01PM
Stifel Maintains Buy on Regenxbio, Maintains $40 Price Target
Benzinga Newsdesk
-
Apr 12, 2024, 11:53AM
Thursday, March 28, 2024
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet Age-Related Macular Degeneration (AMD)
Benzinga Newsdesk
-
Mar 28, 2024, 7:09AM
Monday, March 25, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Mar 25, 2024, 5:32PM
Monday, March 11, 2024
HC Wainwright & Co. Initiates Coverage On Regenxbio with Buy Rating, Announces Price Target of $36
Benzinga Newsdesk
-
Mar 11, 2024, 9:39AM
Friday, March 08, 2024
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
Vandana Singh
-
Mar 8, 2024, 1:43PM
Regenxbio shares are trading higher after RBC Capital upgraded the stock from Sector Perform to Outperform and raised its price target from $20 to $35.
Benzinga Newsdesk
-
Mar 8, 2024, 8:48AM
RBC Capital Upgrades Regenxbio to Outperform, Raises Price Target to $35
Benzinga Newsdesk
-
Mar 8, 2024, 7:59AM
Thursday, March 07, 2024
Chardan Capital Maintains Buy on Regenxbio, Maintains $52 Price Target
Benzinga Newsdesk
-
Mar 7, 2024, 9:45AM
Barclays Maintains Overweight on Regenxbio, Raises Price Target to $55
Benzinga Newsdesk
-
Mar 7, 2024, 7:16AM
REGENXBIO Prices Upsized Public Offering Of 4,565,260 Common Shares At $23/Share And 1,521,740 Pre-Funded Warrants At $22.9999/Warrant
Benzinga Newsdesk
-
Mar 7, 2024, 2:44AM
Wednesday, March 06, 2024
REGENXBIO Announces Proposed $125M Public Offering Of Common Stock
Benzinga Newsdesk
-
Mar 6, 2024, 4:30PM
Leerink Partners Upgrades Regenxbio to Outperform
Benzinga Newsdesk
-
Mar 6, 2024, 9:33AM
Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock
Benzinga Insights
-
Mar 6, 2024, 8:00AM
Baird Maintains Outperform on Regenxbio, Raises Price Target to $39
Benzinga Newsdesk
-
Mar 6, 2024, 7:55AM
Tuesday, March 05, 2024
REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars
Vandana Singh
-
Mar 5, 2024, 12:07PM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Mar 5, 2024, 8:09AM
REGENXBIO shares are trading higher after the company announced new initial efficacy data from its AFFINITY DUCHENNE trial of RGX-202.
Benzinga Newsdesk
-
Mar 5, 2024, 7:36AM
Regenxbio Announces New Initial Efficacy Data From Affinity Duchenne Trial
Benzinga Newsdesk
-
Mar 5, 2024, 7:07AM
Friday, March 01, 2024
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
-
Mar 1, 2024, 1:19PM
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Avi Kapoor
-
Mar 1, 2024, 11:18AM
Wednesday, February 28, 2024
Wedbush Reiterates Neutral on Regenxbio, Maintains $21 Price Target
Benzinga Newsdesk
-
Feb 28, 2024, 8:04AM
Tuesday, February 27, 2024
REGENXBIO Expects Its Balance In Cash & Equivalents Of $314.1M As Of December 31, 2023 To Fund Its Operations Into H2 Of 2025
Benzinga Newsdesk
-
Feb 27, 2024, 4:49PM
Regenxbio: Q4 Earnings Insights
Benzinga Insights
-
Feb 27, 2024, 4:15PM
Regenxbio Q4 2023 GAAP EPS $(1.43) Misses $(1.27) Estimate, Sales $22.21M Miss $34.00M Estimate
Benzinga Newsdesk
-
Feb 27, 2024, 4:11PM
Earnings Scheduled For February 27, 2024
Benzinga Insights
-
Feb 27, 2024, 5:01AM
Monday, February 26, 2024
A Preview Of Regenxbio's Earnings
Benzinga Insights
-
Feb 26, 2024, 12:01PM
Wednesday, February 21, 2024
Raymond James Reinstates Outperform on Regenxbio, Announces $45 Price Target
Benzinga Newsdesk
-
Feb 21, 2024, 5:48AM
Monday, February 12, 2024
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
Vandana Singh
-
Feb 12, 2024, 2:35PM
Wedbush Reiterates Neutral on Regenxbio, Maintains $21 Price Target
Benzinga Newsdesk
-
Feb 12, 2024, 8:25AM
Thursday, February 08, 2024
Jim Cramer Says Investors Should Look Beyond Apple, Meta And Other Magnificent 7 Stocks: 'You Might Be Missing Out On Some Huge Gains'
Benzinga Neuro
-
Feb 8, 2024, 9:34PM
Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?
Vandana Singh
-
Feb 8, 2024, 2:59PM
Wednesday, February 07, 2024
Why Container Store Group Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Feb 7, 2024, 1:02PM
Why Is Gene Therapy-Focused REGENXBIO Stock Trading Higher Today?
Vandana Singh
-
Feb 7, 2024, 12:59PM
REGENXBIO shares are trading higher after the company announced that its pivotal trial of RGX-121 for the treatment of MPS II achieved its primary endpoint.
Benzinga Newsdesk
-
Feb 7, 2024, 12:15PM
REGENXBIO Says As Of January 3, 2024, RGX-121 Continues To Be Well Tolerated In 25 Patients Dosed Across All Phases Of Campsiite Trial
Benzinga Newsdesk
-
Feb 7, 2024, 11:44AM
REGENXBIO Announces Pivotal Trial Of RGX-121 For The Treatment Of MPS II Achieves Primary Endpoint
Benzinga Newsdesk
-
Feb 7, 2024, 11:42AM
Chipotle Posts Upbeat Earnings, Joins Cirrus Logic, Emerson Electric, Carlyle Group And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
-
Feb 7, 2024, 11:38AM
Regenxbio Has Completed Enrollment At Dose Level 2 And Reported Additional Interim Safety And Efficacy In Phase 1/2 AFFINITY DUCHENNE Trial Of Rgx-202 In Patients With Duchenne Muscular Dystrophy Ages 4 To11 Years Old
Benzinga Newsdesk
-
Feb 7, 2024, 7:14AM
Wednesday, January 17, 2024
Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity, Retinal Thickness
Vandana Singh
-
Jan 17, 2024, 3:28PM
Progress Software Posts Strong Q4 Results, Joins Impinj, REGENXBIO And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
Avi Kapoor
-
Jan 17, 2024, 5:32AM
Tuesday, January 16, 2024
REGENXBIO Announced Interim Data from Phase II AAVIATE Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
Charles Gross
-
Jan 16, 2024, 2:51PM
Monday, January 08, 2024
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
-
Jan 8, 2024, 1:36PM
REGENXBIO shares are trading lower after the U.S. District Court issued a decision for the company's and the University of Pennsylvania's NAV Technology Platform patent infringement lawsuit.
Benzinga Newsdesk
-
Jan 8, 2024, 12:20PM
Boeing, Pacific Biosciences of California And Other Big Stocks Moving Lower On Monday
Avi Kapoor
-
Jan 8, 2024, 11:46AM
US District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV Technology Patent Infringement Lawsuit
Benzinga Newsdesk
-
Jan 8, 2024, 7:27AM
Wednesday, November 29, 2023
Regenxbio Announces Dose Escalation In Affinity Duchenne Trial
Benzinga Newsdesk
-
Nov 29, 2023, 7:07AM
Wednesday, November 08, 2023
REGENXBIO Anticipates Total Savings Of At Least $100M Over Next Two Years; Anticipated Cost Savings Along With $365M In Cash, Cash Equivalents And Marketable Securities Expected To Fund Operations Into H2 2025
Benzinga Newsdesk
-
Nov 8, 2023, 5:54PM
Regenxbio Q3 2023 Gaap EPS $(1.41) Beats $(1.49) Estimate, Sales $28.91M Beat $27.19M Estimate
Benzinga Newsdesk
-
Nov 8, 2023, 4:57PM
Earnings Scheduled For November 8, 2023
Benzinga Insights
-
Nov 8, 2023, 4:21AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch